Identification of Clostridium Butyricum and Clostridium Neonatal in the Digestive Microbiota of Premature Infants Before 34 Weeks and Developing or Not Ulcerative Necrotizing Enterocolitis (NEC) During Hospitalization (ECUN-2)
Qualitative and Quantitative Identification of Clostridium Butyricum and Clostridium Neonatal in the Digestive Microbiota of Premature Infants Before 34 Weeks and Developing or Not Ulcerative Necrotizing Enterocolitis (NEC) During Their Hospitalization in Neonatology
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Massimo De Maio
- Phone Number: 04.66.68.33.05
- Email: massimo.dimaio@chu-nimes.fr
Study Locations
-
-
-
Nîmes, France
- CHU de Nîmes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Premature newborn with a term of birth ≤ 34 weeks of gestation admitted to the neonatology department at the CHU of Nîmes.
- Affiliated or beneficiary of a health insurance plan.
- Newborn whose parents received informed information about the study and did not express their opposition to their child's participation in the study.
Exclusion Criteria:
- Newborn with malformative digestive pathology
- Newborn baby participating in another category 1 trial
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Premature neonates with necrotizing enterocolitis
|
Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
|
|
Premature neonates without necrotizing enterocolitis
|
Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Presence of C. butyricum
Time Frame: Each day of hospitalization (maximum 120 days)
|
PCR
|
Each day of hospitalization (maximum 120 days)
|
|
Presence of C. neonatale
Time Frame: Each day of hospitalization (maximum 120 days)
|
PCR
|
Each day of hospitalization (maximum 120 days)
|
|
Culture of C. butyricum
Time Frame: Each day of hospitalization (maximum 120 days)
|
Growth on selective media
|
Each day of hospitalization (maximum 120 days)
|
|
Culture of C. neonatale
Time Frame: Each day of hospitalization (maximum 120 days)
|
Growth on selective media
|
Each day of hospitalization (maximum 120 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Localisation within the hospital
Time Frame: During hospitalization (maximum 120 days)
|
Bed numbers occupied
|
During hospitalization (maximum 120 days)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Age of mother
Time Frame: Day 0
|
Years
|
Day 0
|
|
Body mass index of mother
Time Frame: Day 0
|
Kg/m2
|
Day 0
|
|
Parity of mother
Time Frame: Day 0
|
Day 0
|
|
|
Gravidity of mother
Time Frame: Day 0
|
Day 0
|
|
|
Professional activity of mother
Time Frame: Day 0
|
Yes/no; description
|
Day 0
|
|
Smoking status of mother
Time Frame: Day 0
|
Yes/no
|
Day 0
|
|
Chronic pathology of mother
Time Frame: Day 0
|
Yes/no, description
|
Day 0
|
|
Allergy of mother
Time Frame: Day 0
|
Yes/no, description
|
Day 0
|
|
Number of years of schooling of mother
Time Frame: Day 0
|
Day 0
|
|
|
Exposure to magnesium sulfate during pregnancy
Time Frame: Day 0
|
Yes/no
|
Day 0
|
|
Cause of prematurity
Time Frame: Day 0
|
Day 0
|
|
|
Method of delivery
Time Frame: Day 0
|
Vagina/Caesarean
|
Day 0
|
|
Anesthesia during delivery
Time Frame: Day 0
|
General/spinal
|
Day 0
|
|
Mode of delivery of vaginal birth
Time Frame: Day 0
|
Spontaneous/instrumental
|
Day 0
|
|
Spontaneous rupture of membranes
Time Frame: Day 0
|
Yes/no
|
Day 0
|
|
Time of rupture of membranes before birth
Time Frame: Day 0
|
<12h/>12h
|
Day 0
|
|
Pathology during pregnancy
Time Frame: Day 0
|
Yes/No; description
|
Day 0
|
|
Birth term
Time Frame: Day 0
|
Weeks and days
|
Day 0
|
|
Birth weight
Time Frame: Day 0
|
grams
|
Day 0
|
|
Birth weight percentile
Time Frame: Day 0
|
percentile
|
Day 0
|
|
Birth height
Time Frame: Day 0
|
cm
|
Day 0
|
|
Birth height ; percentile
Time Frame: Day 0
|
percentile
|
Day 0
|
|
Intubation
Time Frame: Day 0
|
Yes/no
|
Day 0
|
|
umbilical venous catheter
Time Frame: Day 0
|
Yes/no; duration
|
Day 0
|
|
Epicutaneo-cava catheter
Time Frame: Day 0
|
Yes/no; duration
|
Day 0
|
|
Daily lipid intake per os per kilp
Time Frame: During hospitlization (maximum 120 days)
|
g/kg
|
During hospitlization (maximum 120 days)
|
|
Presence of sequelae
Time Frame: During hospitalization (maximum 120 days)
|
Yes/no
|
During hospitalization (maximum 120 days)
|
|
Type of sequelae
Time Frame: During hospitalization (maximum 120 days)
|
description
|
During hospitalization (maximum 120 days)
|
|
Hemodynamically significant patent ductus arteriosus
Time Frame: During hospitalization (maximum 120 days)
|
Yes/no
|
During hospitalization (maximum 120 days)
|
|
Type of milk
Time Frame: During hospitalization (maximum 120 days)
|
pasteurized/fresh/artificial
|
During hospitalization (maximum 120 days)
|
|
Duration of milk intake
Time Frame: During hospitalization (maximum 120 days)
|
Days
|
During hospitalization (maximum 120 days)
|
|
Probiotic intake duration
Time Frame: During hospitalization (maximum 120 days)
|
Days
|
During hospitalization (maximum 120 days)
|
|
Types of probiotic taken
Time Frame: During hospitalization (maximum 120 days)
|
Type
|
During hospitalization (maximum 120 days)
|
|
Type of antibiotics taken in post-natal period
Time Frame: During hospitalization (maximum 120 days)
|
Type
|
During hospitalization (maximum 120 days)
|
|
Duration of antibiotic treatment in post-natal period
Time Frame: During hospitalization (maximum 120 days)
|
Days
|
During hospitalization (maximum 120 days)
|
|
Type of vasoactive amines taken
Time Frame: During hospitalization (maximum 120 days)
|
Type
|
During hospitalization (maximum 120 days)
|
|
Duration of vasoactive amine treatment
Time Frame: During hospitalization (maximum 120 days)
|
Days
|
During hospitalization (maximum 120 days)
|
|
Type of any postnatal surgery
Time Frame: During hospitalization (maximum 120 days)
|
Type
|
During hospitalization (maximum 120 days)
|
|
Total duration of parenteral feeding
Time Frame: During hospitalization (maximum 120 days)
|
Days
|
During hospitalization (maximum 120 days)
|
|
Ibuprofen
Time Frame: During hospitalization (maximum 120 days)
|
Yes/no
|
During hospitalization (maximum 120 days)
|
|
Hemodynamic shock
Time Frame: During hospitalization (maximum 120 days)
|
Yes/no
|
During hospitalization (maximum 120 days)
|
|
Labile Blood Product transfusion
Time Frame: During hospitalization (maximum 120 days)
|
Amount
|
During hospitalization (maximum 120 days)
|
|
antenatal corticosteroid therapy
Time Frame: Day 0
|
Complete/incomplete
|
Day 0
|
|
Type of post-natal corticosteroid therapy
Time Frame: During hospitalization (maximum 120 days)
|
Type
|
During hospitalization (maximum 120 days)
|
|
Duration of post-natal corticosteroid therapy
Time Frame: During hospitalization (maximum 120 days)
|
Days
|
During hospitalization (maximum 120 days)
|
|
Exposure to ante- and post-natal antibiotics
Time Frame: During hospitalization (maximum 120 days)
|
Description
|
During hospitalization (maximum 120 days)
|
|
umbilical arterial catheter
Time Frame: Day 0
|
Duration
|
Day 0
|
|
Nosocomial infection
Time Frame: During hospitalization (maximum 120 days)
|
Proven/suspected
|
During hospitalization (maximum 120 days)
|
|
Nosocomial infection infective agent
Time Frame: During hospitalization (maximum 120 days)
|
name
|
During hospitalization (maximum 120 days)
|
|
Rectal bleeding
Time Frame: During hospitalization (maximum 120 days)
|
Number
|
During hospitalization (maximum 120 days)
|
|
metabolic acidosis
Time Frame: During hospitalization (maximum 120 days)
|
Yes/no
|
During hospitalization (maximum 120 days)
|
|
Volume of alimentation per kilo
Time Frame: During hospitalization (maximum 120 days)
|
During hospitalization (maximum 120 days)
|
|
|
Daily carbohydrate intake per os per kilp
Time Frame: During hospitalization (maximum 120 days)
|
g/kg
|
During hospitalization (maximum 120 days)
|
|
Daily proteins intake per os per kilp
Time Frame: During hospitalization (maximum 120 days)
|
g/kg
|
During hospitalization (maximum 120 days)
|
|
Volume of daily total alimentation
Time Frame: During hospitalization (maximum 120 days)
|
During hospitalization (maximum 120 days)
|
|
|
Cranial circumference
Time Frame: Day 0
|
cm; percentile
|
Day 0
|
|
Cranial circumference percentile
Time Frame: Day 0
|
percentile
|
Day 0
|
|
Other catheter
Time Frame: Day 0
|
Type
|
Day 0
|
|
Duration of other catheter
Time Frame: Day 0
|
Days
|
Day 0
|
|
Enriched maternal milk
Time Frame: During hospitalization (maximum 120 days)
|
Maximum percentage
|
During hospitalization (maximum 120 days)
|
|
Milk thickening
Time Frame: During hospitalization (maximum 120 days)
|
Duration
|
During hospitalization (maximum 120 days)
|
|
Chorioamnionitis
Time Frame: During hospitalization (maximum 120 days)
|
Proven/suspected
|
During hospitalization (maximum 120 days)
|
|
Materno-fetal infection
Time Frame: Day 0
|
Proven/suspected
|
Day 0
|
|
Materno-fetal infection infective agent
Time Frame: Day 0
|
name
|
Day 0
|
|
pneumatosis-pneumoportia
Time Frame: During hospitalization (maximum 120 days)
|
Yes/no
|
During hospitalization (maximum 120 days)
|
|
Transfer
Time Frame: During hospitalization (maximum 120 days)
|
Yes/no
|
During hospitalization (maximum 120 days)
|
|
Time of occurence of ulcerative necrotizing enterocolitis
Time Frame: During hospitalization (maximum 120 days)
|
weeks post-natal
|
During hospitalization (maximum 120 days)
|
|
Warning signs of ulcerative necrotizing enterocolitis
Time Frame: During hospitalization (maximum 120 days)
|
During hospitalization (maximum 120 days)
|
|
|
Duration of bowel rest following necrotizing enterocolitis
Time Frame: During hospitalization (maximum 120 days)
|
During hospitalization (maximum 120 days)
|
|
|
Bell staging of ulcerative necrotizing enterocolitis
Time Frame: During hospitalization (maximum 120 days)
|
from IA (suspected necrotizing enterocolitis) to IIIB (advanced necrotizing enterocolitis)
|
During hospitalization (maximum 120 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Massimo De Maio, CHU Nîmes
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIMAO/2019-01/MdM01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.